Hansen Gwenn sold $143K of NRIX
Hansen Gwenn (Chief Scientific Officer) sold 5,409 shares of Nurix Therapeutics, Inc. (NRIX) at an average of $26.42 ($26.28–$26.80, $0.14M total) across 2 trades over 2026-10-30 to 2026-11-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The transaction is small relative to total holdings and follows a pre‑arranged 10b5‑1 plan, suggesting limited informational content for traders.
Market read
A modest insider sell with limited market impact; traders may monitor for larger moves but no immediate actionable signal.
What to watch
Potential upcoming clinical data or partnership announcements could offset the sell pressure.
Background
SEC Form 4 filings provide transparent disclosure of insider transactions. This filing reports a modest sale by a senior officer.
Ticker impact
Form 4 shows Chief Scientific Officer Hansen Gwenn sold $143K of NRIX shares via a 10b5‑1 plan.
likely modest pressure as the market prices in the insider sell
The sale is small relative to holdings and follows a pre‑arranged plan, limiting informational value.
Market effects
Minimal impact on the broader biotech sector.
No regional effect.
Limited to NRIX investors.
Counterpoint
The sale could be routine and not indicative of future performance.
Key entities
- companyNurix Therapeutics, Inc.
Biotech company developing targeted protein degradation therapies.
- personHansen Gwenn
Chief Scientific Officer of Nurix Therapeutics.
